Future Prospects of Global Laboratory Proficiency Testing Market

High blood pressure, abdominal obesity, a round red face, a fatty mass between the shoulders, weak muscles and bones, acne, brittle skin, and other symptoms are all signs of Cushing's syndrome. Pituitary adenoma and multiple endocrine neoplasia are the most common causes of Cushing's syndrome.
Intake of
glucocorticoids recommended by a healthcare professional to treat other
disorders such as asthma, rheumatoid arthritis, or immunosuppression following
an organ transplant is the most common cause of Cushing's syndrome. The disease
can also be caused by the use of synthetic ACTH. Other animals, such as cats,
dogs, and horses, may also be affected. All of the aforementioned causes are
projected to boost the Cushings
syndrome Market.
Crushings Syndrome Market |
Cushing's
syndrome, also known as hypercortisolism, is a hormonal condition characterised
by continuous exposure of bodily tissue to excessive quantities of the hormone
cortisol. Cushing's syndrome affects adults between the ages of 20 and 50. It
is uncommon, however it is at risk of developing in obese patients with type 2
diabetes, high blood pressure, and poorly regulated blood glucose. The Cushing's
syndrome Market is expected to grow due to increased awareness and healthcare
spending. Various new medications, such as ketoconazole, metyrapone, and
mitotane, are now available on the market as a result of increased research and
development to reduce the surgical risk of patients. Cushing's syndrome is expected
to have a yearly incidence of 1–3 cases per million inhabitants, according to
the Orphanet Journal of Rare Disease, but its frequency was close to 40 cases per
million inhabitants in 2012.
Furthermore,
factors contributing to the market's growth include an unhealthy lifestyle, an
increase in the geriatric population, and steroid usage. Difficulties in
diagnosis, a lack of pipeline products, and rigorous restrictions, among other
things, are limiting the global
Cushing's syndrome market's growth.
Market for
Cushing's Syndrome: A Competitive Analysis
Increased
research and development in 2016, like Strongbrigde Biopharma plc's development
of clinical trials for RECORLEV for the treatment of endogenous Cushing's
syndrome, is expected to increase competition and favour growth among
manufacturers to lead the market. Corcept Therapeutics Inc., HRA Pharma,
Strongbridge Biopharma plc., and Novartis AG are among the leading companies in
the Cushing's syndrome industry.
Comments
Post a Comment